Antigen-cloning technique may boost skin cancer vaccine
Skin cancer is a disease in which cancer (malignant) cells are found in the outer layers of skin. The most common types are squamous cell carcinoma and basal cell carcinoma, while the most dangerous is malignant melanoma.
SpiritIndia.com
serving better health information
Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT | Top | Articles

Antigen-cloning technique may boost skin cancer vaccine

Skin Cancer :: Antigen-cloning technique may boost skin cancer vaccine

Skin Cancer :: Antigen-cloning technique may boost skin cancer vaccine

In recent years, researchers have worked to develop a number of vaccines to help the immune system fight tumors. Cancer vaccines are not intended to prevent cancer; rather, they are used to boost immune responses to preexisting tumors.

Unlike traditional chemotherapy, vaccines have relatively low toxicity and, potentially, a high degree of efficacy.

To date, these vaccines have rarely been designed to directly stimulate one of the body's most critical immune responders, the helper T cells. Though helper T cells contain receptors on their cell surfaces that are capable of recognizing and binding to tumor-related antigens, scientists have been stymied by the complex and time-consuming process required to isolate and clone the antigens for vaccine development.

In working to identify a key tumor antigen in melanoma and other cancers, scientists at The Wistar Institute have now developed a novel way to clone an antigen recognized by a helper T cell. Already, Herlyn's group has used the new cloning technique to identify a new tumor antigen called ribosomal protein L8, or RPL8. Findings on the new cloning method and the newly identified tumor antigen will be published as a Priority Report in the April 15 issue of Cancer Research.

The new antigen-cloning approach may allow scientists to design vaccines capable of directly stimulating helper T cells, aiding the development of vaccines not only for cancer but also for infectious diseases, says Dorothee Herlyn, D.V.M., senior author on the study and a professor in the Molecular and Cellular Oncogenesis and Immunology programs at Wistar.

"Most of the melanoma vaccines currently in development work to activate a type of white blood cell called cytotoxic T-lymphocytes, or CTL," says Herlyn. "Though CTL have the ability to destroy cancer cells, they don't have the ability to call upon the full capabilities of the immune system, as do the helper T cells."

(Published at www.spiritindia.com on Monday, April 16, 2007)
»»   Cancer :: Factors attributed to later stage cancer diagnosis identified
««   Cervical Cancer :: Second cancers among survivors of cervical cancer
The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information.
www.spiritindia.com - About us, Editorial Team, Authors, Testimonials, Linking us, Advertising, Advertisers, Recommend us, Feedback, Privacy policy, Disclaimer, Feedback
©2002-2008 SpiritIndia Group